Likitanci
Aikin likitanci fasaha ne, ba sana'ar kasuwanci ba; kira ne, ba kasuwanci ba.
— (1903)
Matasa uku sun kasance da rai ba tare da cuta ba shekaru bayan karɓar T cells na gwaji. Gwajin phase 1 ba zai iya nuna abin da ya jawo waɗannan sakamakon ba
ReMIND ya yi infusion na T cells da aka girma a laboratory daga jinin kowane mara lafiya ga yara da matasa 33 masu high-risk brain tumors. An faɗaɗa sel ɗin domin su amsa ga furotin uku da za su iya kasancewa a cancer cells. Marasa lafiya uku sun sami disease-free intervals fiye da watanni 31.8, 41.2 da 51.6 daga infusion na farko, ciki har da complete response guda ɗaya bisa scan criteria. A aggressive brainstem-tumor group, babu scan da ya nuna isasshen raguwa ko bacewa da ta kai predefined response threshold na trial. Wannan early safety-and-dose trial ɗin ya kuma rubuta mutuwa guda da ta yi tsanani har ta ƙidaya a kan ƙara dose bisa ƙa’idodinsa. Ba tare da comparison group ba, binciken ba zai iya nuna ko T cells ne suka jawo outcomes ukun ba.
KRAS vaccine ya haifar da T cell responses a 18 cikin high-risk participants 20 — ba hujjar cewa yana hana pancreatic cancer ba
Single-centre phase I trial ya gwada six-mutation KRAS peptide vaccine a mutane 20 masu inherited ko familial risk na pancreatic cancer da pancreatic cystic abnormalities. Vaccine-related adverse events sun kasance grade 1 ko 2; mahalarta 18 sun cika prespecified criterion na T cell response a jini; kuma ƙananan analyses sun nuna cewa wasu immune responses sun ci gaba har zuwa shekaru biyu. Babu mahalarci da ya samu pancreatic cancer a median follow-up na watanni 16.5, amma binciken open-label, non-randomized, single-arm ne kuma ba a tsara shi don gwada prevention ba. Vaccine ɗin experimental ne; sakamakon yana goyon bayan larger efficacy trials, ba da'awar cewa an hana cancer ba.
Wani macaque HIV model ya sa rare broad antibodies su bayyana da sauri — clue ga vaccine, ba vaccine tukuna ba
Wani Science study ya engineer SHIV model da ya expose HIV V3-glycan epitope a steps biyu: da farko ta provoking antibodies ga altered V1 loop, sannan ta selecting escape variants da suka buɗe target ga broadly neutralizing antibody precursors. A macaques, engineered virus ya elicit potent V3-glycan broadly neutralizing antibodies a 14 of 22 animals cikin shekara guda, vs none of 14 da parental virus. Result useful blueprint ne ga immunogen design, ba proof cewa HIV vaccine yana aiki a humans ba.
Clinical AI da ya yi kama da safe kuma ya inganta paperwork — amma bai inganta patient outcomes ba
Pragmatic cluster-randomized trial a Kenyan primary care facilities 16 ya gwada generative-AI decision-support tool da aka ƙara ga record da clinical officers suke amfani da shi. A patients 9,691, strict 14-day expert-adjudicated composite na treatment failure ya kasance 2.2% da tool vs 2.0% ba tare da shi ba (adjusted odds ratio 0.77, 95% CI 0.55–1.08, P = 0.13) — babu significant difference. Tool bai nuna safety signal ba, ya improve documentation a duk rated domains, prescribing da satisfaction ba su canza ba, kuma antibiotic costs sun trend down. Wannan ba failed study ba ne; rare, honest one ne — measured on patients, ba benchmarks ba — kuma yana nuna unglamorous truth cewa tool da ya look safe kuma ya help process bai demonstrably help patients cikin weeks biyu ba, kuma detect any such benefit zai buƙaci far larger trial.
Oral norovirus vaccine ya rage infection a challenge trial — amma ya miss clinical endpoint ɗinsa
Phase 2b human-challenge study ya gwada oral tablet vaccine against GI.1 norovirus. Vaccinated adults sun fi ƙarancin qPCR-detectable infection bayan challenge, sun nuna mucosal immune responses, kuma sun shed less viral RNA a wasu time points. Amma prespecified clinical gastroenteritis endpoint ba a meet ba, trial ya yi controlled high-dose challenge a healthy adults, kuma bai measure real-world transmission ko protection against currently dominant GII.4 genotypes ba. Promising step ne toward norovirus vaccine, ba proof cewa ya iso ba.
A beraye, maganin sinadaran girma mai mataki biyu ya sake tsiro da ƙasusuwan yatsar da aka yanke — ba cikakke ba
A yankewar yatsar bera da yawanci take warkewa da tabo, dasa FGF2 sannan BMP2 ya tayar da blastema ya sake gina phalanx da ya ɓace da ƙaramin gaɓa — suna kama da na asali amma ba daidai ba, kuma sun yi nisa da dukan gaɓa. Wannan yana nuna sel da saƙon sake tsiro suna iya kasancewa ko inda dabbobi masu shayarwa yawanci suke kasa: tabbacin ka'ida a bera, ba maganin mutum ba.